This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1dbm
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| + | |||
==MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY== | ==MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY== | ||
<StructureSection load='1dbm' size='340' side='right' caption='[[1dbm]], [[Resolution|resolution]] 2.70Å' scene=''> | <StructureSection load='1dbm' size='340' side='right' caption='[[1dbm]], [[Resolution|resolution]] 2.70Å' scene=''> | ||
| Line 4: | Line 5: | ||
<table><tr><td colspan='2'>[[1dbm]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DBM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1DBM FirstGlance]. <br> | <table><tr><td colspan='2'>[[1dbm]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DBM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1DBM FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SIH:PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE'>SIH</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SIH:PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE'>SIH</scene></td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1dbm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1dbm OCA], [http://pdbe.org/1dbm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1dbm RCSB], [http://www.ebi.ac.uk/pdbsum/1dbm PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1dbm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1dbm OCA], [http://pdbe.org/1dbm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1dbm RCSB], [http://www.ebi.ac.uk/pdbsum/1dbm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=1dbm ProSAT]</span></td></tr> |
</table> | </table> | ||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
| Line 10: | Line 11: | ||
Check<jmol> | Check<jmol> | ||
<jmolCheckbox> | <jmolCheckbox> | ||
| - | <scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/db/1dbm_consurf.spt"</scriptWhenChecked> | + | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/db/1dbm_consurf.spt"</scriptWhenChecked> |
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | ||
<text>to colour the structure by Evolutionary Conservation</text> | <text>to colour the structure by Evolutionary Conservation</text> | ||
| Line 27: | Line 28: | ||
==See Also== | ==See Also== | ||
| - | *[[ | + | *[[3D structures of antibody|3D structures of antibody]] |
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 08:19, 6 December 2017
MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
| |||||||||||
